Talquetamab

• A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematologica… Pending
  2026-525658-13-00 Phase IV 1 country Region Hovedstaden
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 Phase II 4 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting
  2023-506260-14-00 Phase II 2 countries Janssen - Cilag International
• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting
  2024-517382-17-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting
  2023-503442-30-00 Phase III 14 countries Janssen - Cilag International
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended
  2023-508212-38-00 Phase II 3 countries North Estonia Medical Centre Foundation
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended
  2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended
  2024-514016-26-00 Phase II 1 country Fundacion Pethema
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended
  2023-503467-41-00 Phase III 9 countries Janssen - Cilag International
• A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Ended
  2023-503439-16-00 Phase I/II 1 country Janssen - Cilag International
• Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended
  2023-504581-29-00 Phase I (FiH) 6 countries Janssen - Cilag International

Showing 1–13 of 13 trials